New genetic and environmental studies of Parkinson's disease have revealed early problems in synaptic function and connectivity indicating that axonal impairment may be an important hallmark in this disorder. Since many studies suggest that axonal dysfunction precedes cell body loss, it is critical to target axons with treatments aimed at preserving "connectivity" as well as to develop and verify "biomarkers" with which to assess disease progression and drug efficacy.
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine ; Axons ; Disease Progression ; Mitochondria ; Parkinson Disease ; Wallerian Degeneration